Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861749 | 0.87 | CDC7 (0.38) | KCNH2CDC7CYP3A4CYP2D6BRD4 | |
| SCHEMBL27780775 | 0.84 | KCNH2 (0.43) | KCNH2CDC7CYP3A4CYP2D6 | |
| SCHEMBL3863074 | 0.81 | KDM4E (0.38) | KCNH2CDC7CYP3A4BRD4 | |
| SCHEMBL12065904 | 0.80 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL19212781 | 0.79 | KCNH2 (0.45) | KCNH2CDC7BRD4 | |
| SCHEMBL19212756 | 0.78 | KCNH2 (0.44) | KCNH2CYP3A4CYP2D6 | |
| SCHEMBL12066325 | 0.77 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL19231289 | 0.76 | CDC7 (0.45) | KCNH2CDC7BRD4 | |
| SCHEMBL2799933 | 0.76 | BRD4 (0.40) | KCNH2BRD4 | |
| SCHEMBL3858705 | 0.76 | KCNH2 (0.54) | KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055266-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2019-02-21 | — | — | US | disclosed |
| CN-109121397-A | Heterocyclic compound, especially 2- oxo -4,4,5,5,6,6,7,7- octahydro benzoxazoles derivatives and their purposes as antimicrobial compound | 莱德克斯制药公共有限公司 | 2019-01-01 | — | — | CN | disclosed |
| EP-3413976-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | Redx Pharma PLC (GB) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017137744-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055266-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | OXA1L, OGFOD1, OCIAD2 | KCNH2 1227/4885CDC7 281/4885CYP3A4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.